Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | CCR2 | P41597 | 12/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.52 |
| ▸ | CCR4 | P51679 | 3/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CCR5 | P51681 | 1/20 | 0.48 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.44 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.44 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.44 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.44 |
| ▸ | CCR9 | P51686 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12594330 | 0.91 | MEN1 (0.54) | MEN1LMNAKMT2ACCR2CYP2C9 | |
| SCHEMBL10223241 | 0.91 | CCR2 (0.56) | MEN1LMNAKMT2ACCR2CYP2C9 | |
| SCHEMBL12594714 | 0.89 | MEN1 (0.56) | MEN1LMNAKMT2ACCR2CYP2C9 | |
| SCHEMBL10223215 | 0.87 | MEN1 (0.59) | MEN1LMNAKMT2ACCR2CYP2C9 | |
| SCHEMBL12594353 | 0.86 | MEN1 (0.50) | MEN1LMNAKMT2ACCR2CYP2C9 | |
| SCHEMBL305793 | 0.86 | CYP2C9 (0.65) | CCR2CYP2C9CYP3A4 | |
| SCHEMBL12594321 | 0.85 | MEN1 (0.54) | MEN1LMNAKMT2ACCR2CYP2C9 | |
| SCHEMBL10223233 | 0.84 | CCR2 (0.66) | CCR2CYP2C9CYP3A4CYP2C19CCR4 | |
| SCHEMBL12594327 | 0.84 | MEN1 (0.55) | MEN1LMNAKMT2ACCR2CYP2C9 | |
| SCHEMBL12594753 | 0.84 | LMNA (0.61) | MEN1LMNAKMT2ACCR2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170095458-A1 | HETEROARYL SULFONAMIDES AND CCR2/CCR9 | CHEMOCENTRYX, INC. (US) | 2017-04-06 | — | — | US | disclosed |
| US-20140221334-A1 | KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-08-07 | — | — | US | disclosed |
| US-20140031348-A1 | HETEROARYL SULFONAMIDES AND CCR2/CCR9 | CHEMOCENTRYX INC (US) | 2014-01-30 | — | — | US | disclosed |
| US-8519135-B2 | Heteroaryl sulfonamides and CCR2/CCR9 | CHEMOCENTRYX, INC. (US) | 2013-08-27 | — | — | US | disclosed |
| US-20110118248-A1 | Heteroaryl sulfonamides and CCR2/CCR9 | CHEMOCENTRYX, INC. | 2011-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221334-A1 | KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K6 | MEN1 1427/4885LMNA 2030/4885KMT2A 1042/4885 |
| US-20140031348-A1 | HETEROARYL SULFONAMIDES AND CCR2/CCR9 | CCR2, CCR9, CCR1 | MEN1 4873/4885LMNA 4645/4885KMT2A 2475/4885 |
| US-20170095458-A1 | HETEROARYL SULFONAMIDES AND CCR2/CCR9 | CCR2, CCR9, CCR1 | MEN1 4873/4885LMNA 4645/4885KMT2A 2475/4885 |
| US-20110118248-A1 | Heteroaryl sulfonamides and CCR2/CCR9 | CCR2, CCR9, CCR1 | MEN1 4873/4885LMNA 4645/4885KMT2A 2475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.